-
Mashup Score: 2First investigational oral therapy lowers Lp(a) in phase 2 study - 7 hour(s) ago
CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build, and data
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 2First investigational oral therapy lowers Lp(a) in phase 2 study - 10 hour(s) ago
CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build, and data
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet-
📢 Presented at #AHA24: ▶️ Over 12 weeks, #muvalaplin substantially reduced ⬇️ #lipoprotein(a) for adults with elevated levels at high risk for #CV events. ❤️ @American_Heart @HeartNews https://t.co/gNNJY2QOCb
-
📢 Presented at #AHA24: ▶️ Over 12 weeks, #muvalaplin substantially reduced ⬇️ #lipoprotein(a) for adults with elevated levels at high risk for #CV events. ❤️ @American_Heart @HeartNews https://t.co/gNNJY2QOCb